Dane Leone Joins Xencor as Senior Vice President, Corporate Strategy
03 January 2024 - 12:01AM
Business Wire
Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical
company developing engineered antibodies and cytokines for the
treatment of cancer and autoimmune diseases, today announced that
Dane Leone, CFA, has joined Xencor as senior vice president,
corporate strategy. In this newly created role, Mr. Leone will
support the Company’s R&D leadership to enhance value across
Xencor’s platform technologies by overseeing assessment and
prioritization of Xencor’s current and future XmAb® drug
candidates. Mr. Leone has 20 years of experience as a leading
equity research analyst, most recently as a managing director and
senior biotechnology analyst at Raymond James.
“At Xencor, we continuously assess emerging clinical data from
our pipeline programs and the rapidly evolving competitive
landscape to optimize our resource allocation. Dane’s strong track
record of generating unique and insightful industry analyses, along
with engaging closely with clinicians and capital market
participants, complements our research and clinical development
organizations and makes him an important addition to our team,”
said Bassil Dahiyat, Ph.D., president and chief executive officer
at Xencor. “We are grateful to have Dane on board and anticipate
his contributions will help maximize the utility of our platforms
and the value of our clinical programs.”
“Beyond the validation of three commercialized medicines,
Xencor’s XmAb® platforms have yielded a portfolio of internal and
external drug candidates using novel biological mechanisms to
address challenging clinical problems,” said Mr. Leone. “I look
forward to working with Xencor’s R&D team to harness this
approach for the greatest value impact, advancing promising
potential treatment options for patients with cancer and other
serious diseases."
Mr. Leone’s focus areas in equity research included oncology,
immunology, cardiology and ophthalmology. His coverage spanned
securities across a wide range of market capitalization, from
biotechnology companies advancing a diverse set of drug candidates
to commercializing novel medicines. Before Raymond James, Mr. Leone
held analyst roles with increasing seniority at BTIG and Macquarie
Securities Group. He began his career in portfolio management as a
health care and quantitative research analyst at AllianceBernstein.
Mr. Leone received his B.S. in business from the State University
of New York at Albany. He holds the Chartered Financial Analyst®
designation from the CFA® Institute.
CFA® and Chartered Financial Analyst® are registered trademarks
of CFA Institute.
About Xencor
Xencor is a clinical-stage biopharmaceutical company developing
engineered antibodies and cytokines for the treatment of patients
with cancer and autoimmune diseases. More than 20 candidates
engineered with Xencor's XmAb® technology are in clinical
development, and three XmAb medicines are marketed by partners.
Xencor's XmAb engineering technology enables small changes to a
protein's structure that result in new mechanisms of therapeutic
action. For more information, please visit www.xencor.com.
Forward-Looking Statements
Certain statements contained in this press release may
constitute forward-looking statements within the meaning of
applicable securities laws. Forward-looking statements include
statements that are not purely statements of historical fact, and
can generally be identified by the use of words such as
“potential,” “can,” “will,” “plan,” “may,” “could,” “would,”
“expect,” “anticipate,” “seek,” “look forward,” “believe,”
“committed,” “investigational,” and similar terms, or by express or
implied discussions relating to Xencor’s business, including, but
not limited to the quotations from Xencor's president and chief
executive officer, quotations from Xencor’s senior vice president,
corporate strategy and other statements that are not purely
statements of historical fact. Such statements are made on the
basis of the current beliefs, expectations, and assumptions of the
management of Xencor and are subject to significant known and
unknown risks, uncertainties and other factors that may cause
actual results, performance or achievements and the timing of
events to be materially different from those implied by such
statements, and therefore these statements should not be read as
guarantees of future performance or results. Such risks include,
without limitation, the risks associated with the process of
discovering, developing, manufacturing and commercializing drugs
that are safe and effective for use as human therapeutics and other
risks, including the ability of publicly disclosed preliminary
clinical trial data to support continued clinical development and
regulatory approval for specific treatments, in each case as
described in Xencor's public securities filings. For a discussion
of these and other factors, please refer to Xencor's annual report
on Form 10-K for the year ended December 31, 2022 as well as
Xencor's subsequent filings with the Securities and Exchange
Commission. You are cautioned not to place undue reliance on these
forward-looking statements, which speak only as of the date hereof.
This caution is made under the safe harbor provisions of the
Private Securities Litigation Reform Act of 1995, as amended to
date. All forward-looking statements are qualified in their
entirety by this cautionary statement and Xencor undertakes no
obligation to revise or update this press release to reflect events
or circumstances after the date hereof, except as required by
law.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20240102974799/en/
Charles Liles cliles@xencor.com 626-737-8118
For Media: Jason I. Spark Evoke Canale
jason.spark@evokegroup.com 619-849-6005
Xencor (NASDAQ:XNCR)
Historical Stock Chart
From Apr 2024 to May 2024
Xencor (NASDAQ:XNCR)
Historical Stock Chart
From May 2023 to May 2024